Navigation Links
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., , which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announced that Trine Pharmaceuticals, Inc. ("Trine") is presenting a poster detailing the results of a Phase 2a study conducted in 2006 for crofelemer for diarrhoea predominant irritable bowel syndrome (d-IBS) today at Digestive Disease Week in Washington, D.C. Trine licensed crofelemer for the d-IBS indication from Napo in June 2004. Trine has worldwide development and commercialization rights to crofelemer for d-IBS. The objective of the trial was to evaluate the safety and efficacy of crofelemer in men and women with d-IBS.

The trial was designed as a randomized double-blind placebo-controlled, dose-ranging (placebo, 125 mg, 250 mg, and 500 mg bid) study over a 12-week treatment period in 246 patients with d-IBS (Rome II criteria), including both males and females, whose average age was 50 years old.

IBS symptoms (pain, urgency, stool frequency and consistency, and adequate relief) were self-reported by the patients via an interactive voice response system (IVRS). Patients needed to exhibit active disease during the two-week baseline period as defined by a mean daily stool frequency greater than or equal to 2/day, pain score greater than or equal to 1 and stool consistency greater than or equal to 3 (5-point Lickert scale for pain and consistency) to be enrolled. Patients received treatment for 12 weeks followed by a two-week treatment free period.

Results: The 125 mg bid of crofelemer exhibited a consistent response during each month among most efficacy endpoints in women with d-IBS (see table) reaching statistical significance (p<0.05) for pain. Crofelemer had little effect on the stool consistency score, though there was a trend toward redu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/1/2014)... 2014 Quantum Materials Corp (OTCQB:QTMM) today ... photoactive quantum dots for use in next-generation ... advantages for solar power generation, the high cost ... dots with which to develop thin film solar ... utilization and acceptance. The company is also seeking ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... ST. LOUIS, April 21, 2011 / PRNewswire/ ... FDA approved liquid potassium iodide product indicated for thyroid ... has implemented the changes necessary to ramp up production ... ThyroShield is an over-the-counter iodide solution which, ...
... Ind., April 21, 2011 Hill-Rom Holdings, Inc., (NYSE: ... a management presentation at Deutsche Bank,s 36th Annual Health ... 2:10 p.m. ET. You are invited to ... at http://ir.hill-rom.com/events.cfm or access it directly at ...
Cached Medicine Technology:Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield® 2
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... 35% More Weight and Have Better Quality of,Life, ... GAINESVILLE, Fla., Oct. 28 Those patients who ... 35,percent more weight the first year and tend to ... new patient and bariatric surgeon surveys,conducted by Harris Interactive(R), ...
... protect all, studies show shots cut deaths, hospital visits ... people who get the flu vaccine, the better it ... In the first study, researchers from the Institute for ... a universal vaccination program implemented in the Ontario province ...
... Also Underscores High Level of Patient Dissatisfaction with ... am PDT -- UCB announced,today findings from large-scale ... that showed patients rating themselves,as having substantially less ... believed. The survey also showed disagreement between,physicians and ...
... Cardiogenesis,Corporation (Pink Sheets: CGCP), announced that the company ... 30, 2008 prior to market open,on Thursday, November ... P. Lanigan and Senior Vice President and Chief ... conference call that day at 12:00,p.m. Eastern time ...
... Oct. 28 Pharmasset, Inc.,(Nasdaq: VRUS ) today ... American Association for the Study of Liver Diseases (AASLD) ... During this webcast, management,will review Pharmasset,s progress on the ... To access a simultaneous webcast of this event ...
... IOP of 20% from baseline at 12 weeks ... QLTI;,TSX: QLT) ("QLT" or the "Company") today announced data ... by QLT,s wholly-owned subsidiary,QLT Plug Delivery, Inc. (QPD), to ... Delivery System (L-PPDS) for the treatment of open,angle glaucoma ...
Cached Medicine News:Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 2Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 3Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 4Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 5Health News:When It Comes to Flu, the More Who Get Vaccine, the Better 2Health News:New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers 2Health News:New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers 3Health News:New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers 4Health News:New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers 5Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Health News:Pharmasset to Webcast an Investor Event from the AASLD Meeting 3Health News:QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System 2Health News:QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System 3Health News:QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System 4Health News:QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System 5Health News:QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System 6
... Trocar is a full-featured trocar that consists of ... shield. The shield is designed to cover the ... puncture or laceration once the abdominal or thoracic ... option is designed to enhance trocar sleeve fixation ...
... trocar that consists of a sharp pyramidal blade, ... cover the pyramidal tip to protect internal structures ... thoracic cavity has been entered. Due to reduced ... not required. , ,The single-patient use trocar ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: